129 related articles for article (PubMed ID: 36814111)
1. Cuproptosis-related classification and personalized treatment in lower-grade gliomas to prompt precise oncology.
Shen N; Chen S; Liu D; Min X; Tan Q
J Gene Med; 2023 Jun; 25(6):e3486. PubMed ID: 36814111
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.
Shi X; Shi D; Yin Y; Wu Y; Chen W; Yu Y; Wang X
Cell Signal; 2024 May; 117():111072. PubMed ID: 38307306
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
5. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
6. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
7. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.
Huang H; Lv Z; Yang L; Zhang X; Deng Y; Huang Z; Bi H; Sun X; Zhang M; Hu D; Liang H; Hu F
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11499-11515. PubMed ID: 37392200
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
Front Genet; 2023; 14():1124439. PubMed ID: 36936439
[No Abstract] [Full Text] [Related]
11. Cuproptosis facilitates immune activation but promotes immune escape, and a machine learning-based cuproptosis-related signature is identified for predicting prognosis and immunotherapy response of gliomas.
Feng S; Zhang Y; Zhu H; Jian Z; Zeng Z; Ye Y; Li Y; Smerin D; Zhang X; Zou N; Gu L; Xiong X
CNS Neurosci Ther; 2024 Feb; 30(2):e14380. PubMed ID: 37515314
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
14. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
Feng H; Deng Z; Huang Y; Liu Z; Ruan Y; Wang T; Liu J
Front Immunol; 2023; 14():1219209. PubMed ID: 37662947
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes of cuproptosis regulators and their correlation with clinical prognosis and immune response in glioma.
Zhang Y; Dai X; Li Z
Am J Transl Res; 2022; 14(11):8085-8102. PubMed ID: 36505293
[TBL] [Abstract][Full Text] [Related]
18. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
Li W; Zhang X; Chen Y; Pang D
Front Oncol; 2022; 12():966511. PubMed ID: 36212436
[TBL] [Abstract][Full Text] [Related]
19. Identification of cuproptosis-related lncRNAs for prognosis and immunotherapy in glioma.
Wang L; Li Y; Wang Y; Li J; Sun Y; Chen J; Wang Z
J Cell Mol Med; 2022 Dec; 26(23):5820-5831. PubMed ID: 36317420
[TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
